Ypsomed will make injection pens for Novo Nordisk's CagriSema, …
2 days ago · Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...
Ypsomed will make injection pens for Novo Nordisk's CagriSema …
Novo's late-stage trial testing CagriSema is the most advanced of its pipeline of potential drugs and investors say currently the most significant because Novo said it expects the weekly injection ...
“No magic wand” for Novo Nordisk, as CagriSema pen supply …
1 day ago · The Yspsomed deal last year, however, was for various drugs currently undergoing clinical trials, with the Reuters source now confirming this includes CagriSema. Ypsomed, which posted $556m in revenue last year, primarily develops and manufactures injection and infusion systems in the diabetes space.
Novo Nordisk contracts Ypsomed to make CagriSema pens …
1 day ago · CagriSema is designed by combining semaglutide, the active ingredient of Novo’s popular weight loss therapy, Wegovy, with another compound mimicking a metabolic hormone called amylin.
Drugmakers are racing to find the next Wegovy. These obesity …
Oct 10, 2024 · The Danish company is now in late-stage testing with a dual-acting experimental drug it calls cagrisema. The drug combines semaglutide, the active ingredient in Wegovy, with another compound that mimics a metabolic hormone called amylin.
Novo Nordisk tests Wegovy combo against Lilly's Zepbound in …
Nov 15, 2023 · Novo has unveiled a new phase 3 trial pitting CagriSema, a fixed-dose combination of Wegovy and the investigational drug cagrilintide, against Lilly’s Zepbound in people with obesity, according...
Novo Nordisk affirms 25% weight-loss expectation for …
LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO) said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and...
Ozempic Maker Novo Nordisk's New Obesity Drug Targets …
Nov 4, 2024 · Novo Nordisk A/S ’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy, will probably become the world’s top-selling drug franchise next year. It broke open a market...
Novo Nordisk Delivers Updates on Development of Semaglutide, CagriSema …
Mar 7, 2024 · Phase 3 CagriSema Program: Novo Nordisk also offered further insight into its ongoing phase 32 program for cagrisema, a combination of cagrilinitide and semaglutide. Named the REDFINE program, it will feature 6 trials, 5 of which are highlighted below:
Novo Nordisk to affirm superiority of CagriSema in obesity market
Nov 23, 2023 · Novo Nordisk’s phase 3 trial will compare the efficacy and safety of the maximum dose of Zepbound to its late-stage therapy CagriSema, a fixed-dose combination therapy of 2.4mg semaglutide with 2.4mg cagrilintide, in obesity patients.